| 000 | 01907 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516023712.0 | ||
| 264 | 0 | _c20111128 | |
| 008 | 201111s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdq629 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHui, E P | |
| 245 | 0 | 0 |
_aHemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cJun 2011 |
||
| 300 |
_a1280-1287 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aCarcinoma |
| 650 | 0 | 4 | _aChemoradiotherapy |
| 650 | 0 | 4 |
_aEpistaxis _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematemesis _xchemically induced |
| 650 | 0 | 4 |
_aHemoptysis _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNasopharyngeal Carcinoma |
| 650 | 0 | 4 |
_aNasopharyngeal Neoplasms _xtherapy |
| 650 | 0 | 4 |
_aPyrroles _xadverse effects |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSunitinib |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMa, B B Y | |
| 700 | 1 | _aKing, A D | |
| 700 | 1 | _aMo, F | |
| 700 | 1 | _aChan, S L | |
| 700 | 1 | _aKam, M K M | |
| 700 | 1 | _aLoong, H H | |
| 700 | 1 | _aAhuja, A T | |
| 700 | 1 | _aZee, B C Y | |
| 700 | 1 | _aChan, A T C | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 22 _gno. 6 _gp. 1280-1287 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdq629 _zAvailable from publisher's website |
| 999 |
_c20594671 _d20594671 |
||